Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The FDA’s support is a critical milestone for Lantern Pharma, as it validates the company’s precision oncology approach using its proprietary RADR platform. The HARMONIC trial is specifically designed to address an unmet medical need in never-smoker patients with advanced lung adenocarcinoma who have relapsed after tyrosine kinase inhibitor (TKI) treatment. By honing in on the EGFR exon 21 L858R mutation subgroup, Lantern aims to maximize the therapeutic potential of LP-300, a cisplatin/ethacraplatin analog that may overcome resistance mechanisms common in this population.
This development underscores the importance of biomarker-driven clinical trials in oncology. Lantern’s ability to leverage AI and machine learning through its RADR platform to identify patient subgroups most likely to benefit from LP-300 could accelerate the drug’s development and improve outcomes for a patient population with limited options. The company’s focus on never-smokers with lung cancer is particularly noteworthy, as this group often has distinct molecular profiles and treatment responses compared to smokers.
Lantern Pharma is a clinical-stage precision oncology company that uses its proprietary RADR platform to transform cancer therapy development. Beyond LP-300, its pipeline includes LP-184 (acylfulvene) and LP-284, a TC-NER targeting compound for hematologic and solid tumors. Additionally, Lantern’s subsidiary, Starlight Therapeutics, is developing LP-184 for pediatric CNS cancers. The company also recently launched Zeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research tool, representing a new revenue stream.
For more details on the FDA’s response and the HARMONIC trial, the full press release is available at https://ibn.fm/Rxklm. Investors seeking the latest news and updates on Lantern Pharma can visit the company’s newsroom at https://ibn.fm/LTRN.
